Piloting a new course to reimbursing antibiotics

The shockingly fast speed at which COVID-19 turned from a regional breakout to a global pandemic with no treatments has made it easy to imagine a similar epidemic arising from multi-drug resistant bacteria, adding new urgency to the need to fix the dysfunctional market for antibiotics.

Antibiotic development is stuck in a negative feedback loop -- with no viable commercial market for new therapies, R&D investment has nearly disappeared...